ArticleBMC cancer2025
Anti-thyroglobulin antibody levels post-thyroidectomy and papillary thyroid carcinoma recurrence.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.Annals of medicine · 2026Article
- Treatment strategies for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis: a narrative review.Gland surgery · 2026Review
- Article
- Exploratory Statistical Analyses of Clinical and Biochemical Factors for Differentiated Thyroid Cancer from a Romanian Cohort.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global incidence of thyroid cancer, particularly papillary thyroid carcinoma (PTC), is rising due to more frequent incidental findings. Despite a high 10-year survival rate of 93%, up to 28% of PTC patients experience locoregional recurrence. Postoperative monitoring typically relies on serum thyroglobulin (Tg), but the presence of anti-thyroglobulin antibodies (TgAb) interferes with Tg measurement, necessitating reliable detection methods. This study aimed to assess the predictive value of postoperative TgAb levels for PTC recurrence and establish a TgAb threshold as a prognostic marker.
methodA retrospective analysis was conducted on 15,620 patients who underwent bilateral total thyroidectomies at Gangnam Severance Hospital between March 2004 and December 2022. After excluding patients with unmeasurable postoperative TgAb or other carcinoma types, the final cohort comprised 4,434 PTC patients (775 men and 3,659 women, median age 46 ± 11.68 years). Bilateral total thyroidectomy was performed on all patients. TgAb levels were measured 2 days post-surgery and annually, with the most recent levels used for analysis. The primary outcome was PTC recurrence, analyzed based on stratified TgAb levels.
resultsElevated TgAb levels were significantly associated with increased tumor size and recurrence rates (P < 0.001). Patients with TgAb levels above 440 IU/mL showed a higher recurrence rate (13.3%) compared to those with lower levels. A TgAb threshold of 440 IU/mL was identified as a novel recurrence marker, with an odds ratio of 6.0 (95% CI: 2.987-12.053, P < 0.0001). The disease-free survival (DFS) was shorter in patients with TgAb levels above this threshold.
conclusionsPostoperative TgAb levels are a useful prognostic indicator for PTC recurrence, with a proposed threshold of 440 IU/mL serving as a predictive marker. This threshold provides valuable insight for monitoring patients, irrespective of test timing post-surgery, and may guide clinical decision-making for identifying high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.